Two-drug regimen of dolutegravir plus lamivudine (DTG+3TC) is noninferior to dolutegravir plus tenofovir/emtricitabine (DTG+TDF/FTC) at 48 weeks in antiretroviral treatment-naive adults with HIV-1 infection: subgroup analyses in the GEMINI studies.

MLA

Orkin, C., et al. “Two-Drug Regimen of Dolutegravir plus Lamivudine (DTG+3TC) Is Noninferior to Dolutegravir plus Tenofovir/Emtricitabine (DTG+TDF/FTC) at 48 Weeks in Antiretroviral Treatment-Naive Adults with HIV-1 Infection: Subgroup Analyses in the GEMINI Studies.” Journal of Infection & Public Health, vol. 12, no. 1, Jan. 2019, p. 147. EBSCOhost, https://doi.org/10.1016/j.jiph.2018.10.127.

APA

Orkin, C., Porteiro, N., Berhe, M., Dretler, R., Viciana, P., Tseng, Y., Oprea, C., Johnson, M., Kulagin, V., Man, C., Sievers, J., Currie, A., Underwood, M., Tenorio, A., Pappa, K., Wynne, B., Aboud, M., Smith, K., Gartland, M., & Steinhart, C. (2019). Two-drug regimen of dolutegravir plus lamivudine (DTG+3TC) is noninferior to dolutegravir plus tenofovir/emtricitabine (DTG+TDF/FTC) at 48 weeks in antiretroviral treatment-naive adults with HIV-1 infection: subgroup analyses in the GEMINI studies. Journal of Infection & Public Health, 12(1), 147. https://doi.org/10.1016/j.jiph.2018.10.127

Chicago

Orkin, C., N. Porteiro, M. Berhe, R. Dretler, P. Viciana, Y. Tseng, C. Oprea, et al. 2019. “Two-Drug Regimen of Dolutegravir plus Lamivudine (DTG+3TC) Is Noninferior to Dolutegravir plus Tenofovir/Emtricitabine (DTG+TDF/FTC) at 48 Weeks in Antiretroviral Treatment-Naive Adults with HIV-1 Infection: Subgroup Analyses in the GEMINI Studies.” Journal of Infection & Public Health 12 (1): 147. doi:10.1016/j.jiph.2018.10.127.